Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 10/20 | 0.37 |
| ▸ | KDR | P35968 | 6/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28427303 | 0.83 | EGFR (0.60) | EPHA2KDRERBB2MEN1ALDH1A1 | |
| SCHEMBL6380197 | 0.82 | IRAK4 (0.33) | ENPP1ALDH1A1 | |
| SCHEMBL22394465 | 0.81 | EGFR (0.61) | EPHA2KDRERBB2EPHB4MAPT | |
| SCHEMBL28428839 | 0.81 | KDR (0.52) | EPHA2KDRERBB2EPHB4MAPT | |
| SCHEMBL28424820 | 0.81 | EGFR (0.58) | EPHA2KDREPHB4FLT1EGFR | |
| Hydrochloric Acid SCHEMBL28384466 | 0.81 | EGFR (0.60) | EPHA2KDRERBB2EPHB4MAPT | |
| SCHEMBL15520007 | 0.77 | ENPP1 (0.56) | ENPP1PDE10AEPHA2KDRERBB2 | |
| SCHEMBL23368184 | 0.75 | ENPP1 (0.72) | ENPP1KDRPDE1BFLT1ALDH1A1 | |
| SCHEMBL15878766 | 0.74 | AXL (0.55) | KDR | |
| SCHEMBL15519473 | 0.73 | HDAC1 (0.61) | KDRALDH1A1MAPTEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108999-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-114920704-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-115108999-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-09-27 | — | — | CN | disclosed |
| CN-114920704-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-08-19 | — | — | CN | disclosed |
| CN-112300082-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-04-26 | — | — | CN | disclosed |
| CN-112300082-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2021-02-02 | — | — | CN | disclosed |
| US-9034886-B2 | 4-aminoquinazoline derivatives and uses thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-05-19 | — | — | US | disclosed |
| US-20140235633-A1 | 4-Aminoquinazoline Derivatives and Uses Thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-08-21 | — | — | US | disclosed |
| EP-2708532-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND USES THEREOF | Jiangsu Hengyi Pharmaceutical Co.,Ltd (CN) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235633-A1 | 4-Aminoquinazoline Derivatives and Uses Thereof | HDAC5, HDAC4, HDAC1 | ENPP1 3847/4885PDE10A 3162/4885EPHA2 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.